logo-loader
viewBioLargo, Inc.

BioLargo completes prototype for PFAS treatment system, ready for pilot testing

BioLargo (OTCQB: BLGO) CEO Dennis Calvert Calvert joined Steve Darling from Proactive with news the company has completed manufacturing on its first prototype unit of their patented BioLargo AEC to tackle PFAS contamination.

Calvert told Proactive the next step and he also told investors about a new product from their Clyra Medical called Clyraguard.

Quick facts: BioLargo, Inc.

Price: 0.1749 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $30.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

i3 Energy team detail £30mln fundraise and Canada growth strategy

i3 Energy PLC's (LON:I3E) Majid Shafiq and Graham Heath speak to Proactive's Andrew Scott soon after confirming they've raised at least £29mln, with a further £1mln subject to regulatory approval. The company last week struck a deal to concurrently sell a package of the Gain assets to a third...

21 minutes ago

2 min read